30 closest matches · ranked by relevance
Anaplastic Ependymoma · Brain Ependymoma · Cellular Ependymoma
Primary: Event-free Survival (EFS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or…
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 0.614; 0.685; 0.372 Probability of EFS at 5 years
Recurrent Childhood Ependymoma
Primary: Objective Response Rate (Complete Response Rate and Partial Response Rate) Following Treatment With Everolimus for Children With Recurrent or Progressive Ependymomas…
Ependymoma · Anaplastic Ependymoma
Primary: Percentage of Participants That Have Progressive Free Survival (PFS) After 1 Year — 76.4 Percentage of participants
Childhood Cerebellar Anaplastic Astrocytoma · Childhood Cerebral Anaplastic Astrocytoma · Childhood Cerebral Astrocytoma
Primary: Sustained Objective Response Rate — 0; 0 percentage of patients
Brain Tumors · Spinal Cord Tumors
Primary: Time to Progression — 7.8 Months
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Pediatric Recurrent Progressive Low-grade Gliomas · Pediatric Progressive Low-grade Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months — 67 percentage
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Central Nervous System Nongerminomatous Germ Cell Tumor · Childhood Germinoma
Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Glioblastoma · Malignant Glioma · Medulloblastoma Recurrent
Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Recurrent High Grade Meningioma
Primary: Progression Free Survival (PFS) — 4.17; 2.43 Months — p=0.204
Childhood High-grade Cerebellar Astrocytoma · Childhood High-grade Cerebral Astrocytoma · Recurrent Childhood Anaplastic Astrocytoma
Primary: Objective Response to Cilengitide — 1; 23 participants
Brain Cancer · Pediatric Cancers
Primary: Objective Response Rate — 0 Percentage of Participants
Brain Stem Gliomas
Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
Neurofibromatosis Type 1 · Recurrent Childhood Pilocytic Astrocytoma · Recurrent Childhood Visual Pathway Glioma
Primary: Number of Patients Who Demonstrate Complete or Partial Response — 4; 4 Participants
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival (PFS) of Low Grade Glioma Patients Treated With Autologous Dendritic Cells Pulsed With Autologous Tumor Lysate — 0; 1; 1; 1 participants